New Oxygen Conserver Receives FDA Clearance
CHAD Therapeutics Inc., Chatsworth, announced clearance by the Food and Drug Administration to market its new Oxymatic 401 electronic oxygen conserver. The device is designed to extend the life of portable oxygen systems.
The company produces and distributes oxygen-conserving devices and oxygen systems used by pulmonary patients who need supplemental oxygen.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
